Company
Sagimet Biosciences
We are a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate.
Also known as Sagimet Biosciences Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Sagimet Biosciences Inc.
Record updated 28 September 2026
About
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, metabolic dysfunction-associated steatohepatitis (MASH), and certain FASN-dependent tumor types.
Funding snapshot
- Total raised
- $167MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $69M2020-12-21
Funding rounds
- Round, 2020
- $69M2020-12-21, SEC form D sold, 13 investors
- Round, 2019
- $35.2M2019-02-12, SEC form D sold, 19 investors
- Round, 2016
- $5.4M2016-06-17, SEC form D sold, 7 investors
- Round, 2014
- $14.3M2014-10-22, SEC form D sold, 12 investors
- Round, 2013
- $7.5M2013-06-14, SEC form D sold, 2 investors
- Round, 2011
- $20.1M2011-11-29, SEC form D sold, 3 investors
- Round, 2009
- $15M2009-07-07, SEC form D sold, 4 investors
About the company
- Status notes
- clinical-stage biopharmaceutical company
Products
- Other
- denifanstat